NEWDRU / ANNUAL
No resting orders on this market.
Resolves Yes if Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.